These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 6734803)
1. [Pharmacokinetic characteristics of zixoryn used in single and multiple doses]. Kuz'min AI; Kukes VG; Chekhmakina OV Farmakol Toksikol; 1984; 47(3):108-14. PubMed ID: 6734803 [TBL] [Abstract][Full Text] [Related]
2. Combined effect of alpha-methyldopa and a new enzyme inducer, Zixoryn, on the hepatic mixed-function monooxygenase system in humans. Gachályi B; Vas A; Káldor A Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):183-5. PubMed ID: 6862721 [TBL] [Abstract][Full Text] [Related]
3. [The effectiveness of using the enzyme inducer zixorin in the complex treatment of patients with viral hepatitis A]. Gnoevoĭ VB; Maksin VR; Zaika VI; Mosichev IuN Voen Med Zh; 1989 Jun; (6):38-9. PubMed ID: 2800400 [No Abstract] [Full Text] [Related]
4. [The correction of the liver detoxifying function with phenobarbital and ziksorin before and after ischemia]. Grek OR; Rybakova TA; Sharapov VI; Zakharova MV; Shkurupiĭ VA Eksp Klin Farmakol; 1993; 56(5):30-3. PubMed ID: 8312805 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783 [TBL] [Abstract][Full Text] [Related]
6. Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers. Vezekenyi Z; Ferenci J; Radnai B; Horvath T; Past T; Nagy L; Jávor T Int J Clin Pharmacol Res; 1983; 3(2):77-88. PubMed ID: 6679516 [TBL] [Abstract][Full Text] [Related]
7. [Enzyme inductive effect of zixoryn (3-trifluoromethyl-alpha-ethyl-benzhydrol) in neonatal jaundice]. Korányi G; Boross G Monatsschr Kinderheilkd; 1985 Feb; 133(2):99-101. PubMed ID: 3982427 [TBL] [Abstract][Full Text] [Related]
8. [Enzyme induction in the liver changes drug activity]. Greim H Med Klin; 1980 Sep; 75(20):709-12. PubMed ID: 6999314 [No Abstract] [Full Text] [Related]
9. [Effect of microsomal monooxygenase inductor zixoryn on clinico-immunologic indicators in allergologic patients]. Lozovoĭ VP; Vol'skii NN; Nepomniashchikh VM; Tananko EM; Nosikova TA Ter Arkh; 1987; 59(2):7-9. PubMed ID: 3576481 [TBL] [Abstract][Full Text] [Related]
10. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Amacher DE; Beck R; Schomaker SJ; Kenny CV Toxicol Appl Pharmacol; 1997 Jan; 142(1):143-50. PubMed ID: 9007043 [TBL] [Abstract][Full Text] [Related]
11. Species differences in responsiveness to 1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene, a potent phenobarbital-like inducer of microsomal monooxygenase activity. Poland A; Mak I; Glover E Mol Pharmacol; 1981 Sep; 20(2):442-50. PubMed ID: 7300821 [No Abstract] [Full Text] [Related]
12. Effects of lipid ingestion on the induction of drug metabolizing enzymes of nuclear envelope and microsomes by phenobarbital. Cheng KC; Ragland WL; Wade AE J Environ Pathol Toxicol; 1980 Aug; 4(1):219-35. PubMed ID: 7441111 [No Abstract] [Full Text] [Related]
13. [Effect of zixoryn on diuresis and renal transport of xenobiotics]. Astaf'eva EP; Berkhin EB; Ul'ianov GP Biull Eksp Biol Med; 1987 Nov; 104(11):602-3. PubMed ID: 3676500 [TBL] [Abstract][Full Text] [Related]
14. Relationship between hepatic metabolism of chlorpromazine and cholestatic effects in the isolated perfused rat liver. Tavoloni N; Boyer JL J Pharmacol Exp Ther; 1980 Aug; 214(2):269-74. PubMed ID: 7391977 [No Abstract] [Full Text] [Related]
15. Phenobarbital induction of hepatic CYP2B1 and CYP2B2: pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Agrawal AK; Shapiro BH Mol Pharmacol; 1996 Mar; 49(3):523-31. PubMed ID: 8643092 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of arrhythmia in patients with chronic ischemic heart disease using kinilentin combined with an inhibitor or inductor of microsomal oxidation]. Kharlamova IV; Sivkov II; Starodubtsev AK; Bogovskiĭ BP; Blinkov IL; Rubin MP Sov Med; 1989; (12):41-4. PubMed ID: 2631246 [No Abstract] [Full Text] [Related]
17. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Comparison with troleandomycin. Pessayre D; Descatoire V; Tinel M; Larrey D J Pharmacol Exp Ther; 1982 Apr; 221(1):215-21. PubMed ID: 6977641 [No Abstract] [Full Text] [Related]
18. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648 [TBL] [Abstract][Full Text] [Related]
19. Hormonal environment and age influencing the activity of flumecinol, a synthetic enzyme inducer. Kulsár-Gergely J; Kulcsár A Arzneimittelforschung; 1981; 31(12):2101-3. PubMed ID: 7199306 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic studies of flumecinol in man and dog. Klebovich I; Vereczkey L; Kerpel-Fronius S; Ringwald G; Bodrogligeti I Eur J Drug Metab Pharmacokinet; 1982; 7(2):99-104. PubMed ID: 7117300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]